Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia.

By J. Friedberg, J. Sharman, J. Sweetenham, P. Johnston, J. Vose, A. LaCasce, Julia Schaefer-Cutillo, Sven De Vos, R. Sinha, J. Leonard and 6 more. Blood, 2010

801 citations recorded by the source corpus.

Subfields: Genetics, Hematology, Pathology and Forensic Medicine

View Paper: https://www.semanticscholar.org/paper/c949f00bf333a9ddc3195eca95d9fd59459895f4

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Genetics

1. A. Mócsai
2. Eric S. Lander

Citations in the corpus

• Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing (2012, background): “For example, the tyrosine kinase SYK was identified as a likely driver based on these criteria, and it has recently been demonstrated that SYK inhibitors have significant clinical activity in non-Hodgkin lymphoma, including DLBCL (38, 39).”
• The SYK tyrosine kinase: a crucial player in diverse biological functions (2010, background): “, and fostamatinib therapy prolonged the survival of patients with diverse types of B cell lymphoma or B cell lineage CL”
• Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib. (2015, neutral): “Median age, years (range) 71 (65-84) 64 (37-82) 68 (37-84)”